Treatment of menopausal syndrome - Current literature review;A menopausás tünetegyüttes kezelése az elmúlt évek szakirodalmi adatainak tükrében

Orvosi Hetilap

Volumn 147, Issue 19, 2006, Pages 879-885

  Magyar, Zoltán ^a,b   Fél, Tamás ^b  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b Orvosi Osztály ^*

Author keywords

Fracture; Hotflash; Menopuse; Osteoporosis

Indexed keywords

ALGESTONE; CALCIUM; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTRADIOL; ESTROGEN; MEDROXYPROGESTERONE; NORETHISTERONE ACETATE; PLACEBO; PROGESTERONE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TIBOLONE; VITAMIN D;

AGING; CLINICAL TRIAL; COGNITIVE DEFECT; CYSTITIS; DEPRESSION; DISEASE PREDISPOSITION; ENDOMETRIUM ATROPHY; ESTROGEN DEFICIENCY; FATIGUE; FEMALE; HEART PALPITATION; HIP FRACTURE; HORMONAL THERAPY; HOT FLUSH; HUMAN; HUNGARY; ISCHEMIC HEART DISEASE; LIBIDO DISORDER; LIFESPAN; MENOPAUSAL SYNDROME; MENOPAUSE; OSTEOPOROSIS; PANIC; PUBLIC HEALTH; QUALITY OF LIFE; REVIEW; SEXUAL AROUSAL DISORDER; SWEATING; SYMPTOMATOLOGY; URINE INCONTINENCE; VAGINAL DRYNESS; VASOMOTOR DISORDER; VERTEBRA FRACTURE; ATROPHY; BLOOD; ENDOMETRIUM; ESTROGEN THERAPY; FRACTURE; HEART MUSCLE ISCHEMIA; LIBIDO; METHODOLOGY; MIDDLE AGED; PATHOLOGY; POSTMENOPAUSE OSTEOPOROSIS; PSYCHOLOGICAL ASPECT; SPINE FRACTURE; TACHYCARDIA; VAGINA;

ATROPHY; CLINICAL TRIALS; COGNITION DISORDERS; CYSTITIS; DEPRESSION; ENDOMETRIUM; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FATIGUE; FEMALE; FRACTURES, BONE; HIP FRACTURES; HOT FLASHES; HUMANS; HUNGARY; LIBIDO; MENOPAUSE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; OSTEOPOROSIS, POSTMENOPAUSAL; PANIC DISORDER; SPINAL FRACTURES; SWEATING; TACHYCARDIA; URINARY INCONTINENCE; VAGINA;

EID: 33746084921     PISSN: 00306002     EISSN: 17886120     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Barrett-Connor E., Grady D., Sashegyi A. és mtsai: Raloxifen és az osteoporoticus, postmenopausalis nok cardiovascularis eseményei. JAMA-HU, 2002, 5, 363-375.
2. Cauley, J. A., Norton, L., Lippman, M. E. és mtsai: Risk of mortality following clinical fractures. Osteoporos. Int., 2000, 11, 556-561.
3. Collaborative Group on Hormonal Factors in Breast Cancer: Breast cancer and hormone replacement therapy combined reanalysis of data from 51 epidemiological studies involving 52705 women with breast cancer and 108411 women without breast cancer. Lancet, 1997, 350, 1047-1059.
4. Egarter, Ch., Huber, J., Leikermoser, R. és mtsai: Tibolone versus conjugated estrogens and sequential progestigen int he treatment of climacteric complaints. Maturitas, 1996, 23, 55-62.
5. Ettinder, B., Black, B. M., Mitlak, B. H. és mtsai: Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with Raloxifene JAMA, 1999, 282, 637-645.
6. Genazzani, A. R., Petraglia, F., Facchinetti, F. és mtsai: Effects of OD 14 on pituitary and peripheral Bendorphin in castrated rats and in postmenopusal women. Maturitas, 1987, 1, 35-48.
7. Grady, D., Herrington, D., Bittner, V. és mtsai: Cardiovascular disease outcomes during 6.8 years of hormone therapy. JAMA, 2002, 288, 49-57.
8. Hammar, M., Christau, S., Nathorst-Boeoes, J. és mtsai: A double-blind, randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms. Br. J. Obstet. Gynaecol., 1998, 105, 904-911.
9. Helmond, F.: Tibolone in a class of its own! The STEAR concept. 4th Word Congress on Controversies in Obstetrics and Gynecology and Infertiliy., 2003, 24-27. old.
10. Helmond, F. A., Coelingh-Bennink, H. J. T., Langren, M. B. és mtsai: Dose-response analysis of effects of tibolone on climacteric symphtoms in highly symptomatic subjects with at least seven hot flashes ans sweats/day. In: Abstracts and posters on Livial (tibolone): 9th International Menopause Symposium, 1999, 17-21. old.
11. Hulley, S., Grady, D., Bush. T. és mtsai: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart d isease in postmenopausal women: Heart and Estrogen/progestin Replacement Study (HERS) JAMA, 1998, 280, 605-613.
12. Kloosterboer, H. J., Ederveen, A. G. H.: Pros and cons of existing treatment modalities in osteoporosis: a comparison between tibolone, SERM and estrogen (progestogen) treatments. J. Ster. Biochem. Mol. Biol., 2003, 83, 157-165.
13. Lakatos P., Horváth Cs., Marton I. és mtsai: Ajánlás az involúciós osteoporosisok gyógyszeres kezelésére. Ca és Csont, 2000, 3, 169-173.
14. Langren, M. B., Coelingh-Bennink, H. J. T, Helmond, F. A. és mtsa: Dose-response analysis of effects of tibolone on climacteric symphtoms. Br. J. Obstet. Gynecol., 2002, 109, 1109-1114.
15. Lyritis, G. P., Karpathios, S., Basdekis, K. és mtsai: Prevention of post-oophorectomy bone loss with tibolone. Maturitas, 1995, 22, 247-253.
16. Mendelsohn, M., Karas, R.: The protective effects of estrogen on the cardiovascular system. N. Engl. J. Med., 1999, 340, 1801-1811.
17. Nathorst-Böös, J., Hammar, M.: Effect on sexual life - a comparison between tibolone and continuous estradiol-norethisterone acetate regomen. Maturitas, 1997, 26, 15-20.
18. Rijpkema, A. H., van der Sanden, A. A., Ruijs, A. H.: Effects of postmenopausal estrogen-progesterone therapy on serum lipids,and lipoproteins. Maturitas, 1990, 12, 259-285.
19. Rymer, J., Chapman, M. G., Fogelman, I.: A study of the effect of tibolone on the vagina in postmenopusal women. Maturitas, 1994, 18, 127-133.
20. Rymer, J., Robinson, J., Fogelman, I.: Ten years of treatment with tibolone 2,5 mg daily: effects on bone loss in postmenopusal women Climacteric, 2002, 5, 390-398.
21. Rymer, J., Robinson, J., Fogelman, I.: Effects of 8 years of treatment with tibolone 2.5mg daily on postmenopausal bone loss. Osteoporos. Int, 2001, 12, 478-483.
22. Schairer C., Lublin, J., Troisi, R. és mtsai: Menopausal estrogen and estrogen-progestin replacement therapy and brest cancer risk. JAMA, 2000, 283, 485-491.
23. Schoulz, B.: The effects of tibolone and conventional HRT in breast cell proliferation and mammographic density. Climacteric, 2002, 5 (Suppl. 1.), 216.
24. Simon J. A., Hsia, J., Cauley, J. A. és mtsai: Postmenopausal hormone therapy and risk of stroke (HERS). Circulation, 2001, 103, 638-642.
25. Speroff, L.: The Million Women Study and breast cancer. Maturitas, 2003, 46, 1-6.
26. Tax, L., Goorissen, E. M., Kicovic, P. M.: Clinical profile of Org OD 14. Maturitas, 1987, 1, 3-13.
27. Vos, R. M., Krebbers, S., Verhoeven, C. és mtsa: In vivo human metabolism of tibolone. Drug Metab. Dispos., 2002, 30, 106-122.
28. Völker, W, Coelingh-Bennink, H. J. T., Helmond, F. A.: Effects of tibolone on the endometrium Climacteric, 2001, 4, 203-208.
29. Writing Group of the PEPI Trial: Judd HL, (principal investigator) University of California: Effects of hormone therapy on bone mineral density: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. JAMA, 1996, 276, 1389-1396.
30. Writing Group of the WHI Trial: Anderson GL, (writing group chair) Fred Hutchinson Cancer Research Center, Seattle: Effects of conjugated equin estrogens in postmenopausal women with hysterectomy; the WHI randomised, controlled trial. JAMA, 2004, 291, 1701-1712.
31. Writing Group of the Women's Health Initiative Investigators: Anderson GL, (Co-principal investigator)WHI Clinical Coordinating Center: Risk and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA, 2002, 288, 321-333.